148 related articles for article (PubMed ID: 25754282)
21. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
[TBL] [Abstract][Full Text] [Related]
22. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
[TBL] [Abstract][Full Text] [Related]
23. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.
Wu TL; Chang CP; Tsao KC; Sun CF; Wu JT
J Clin Lab Anal; 1999; 13(6):312-9. PubMed ID: 10633301
[TBL] [Abstract][Full Text] [Related]
24. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
25. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
26. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
27. Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szücs M; Nyirády P; Romics I; Rübben H; Szarvas T
Pathol Oncol Res; 2017 Jul; 23(3):643-650. PubMed ID: 28012116
[TBL] [Abstract][Full Text] [Related]
28. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
29. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
30. The role of chromogranin A in the management of patients with phaeochromocytoma.
Grossrubatscher E; Dalino P; Vignati F; Gambacorta M; Pugliese R; Boniardi M; Rossetti O; Marocchi A; Bertuzzi M; Loli P
Clin Endocrinol (Oxf); 2006 Sep; 65(3):287-93. PubMed ID: 16918946
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the automated KRYPTOR chromogranin A assay with the DAKO ELISA.
Wolf M; Riedlinger I; Lehmann R; Häring HU; Schleicher E; Peter A
Clin Lab; 2014; 60(12):2103-6. PubMed ID: 25651748
[TBL] [Abstract][Full Text] [Related]
33. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significant of serum chromogranin A levels for diagnosing pheochromocytoma in hypertensive patients].
Biausque F; Jaboureck O; Devos P; D'Herbomez M; Hainaut P; Carré A; Mounier-Vehier C
Arch Mal Coeur Vaiss; 2003; 96(7-8):780-3. PubMed ID: 12945223
[TBL] [Abstract][Full Text] [Related]
35. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
38. A comparison between three commercial kits for chromogranin A measurements.
Stridsberg M; Eriksson B; Oberg K; Janson ET
J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
[TBL] [Abstract][Full Text] [Related]
39. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.
Tartaglia A; Portela-Gomes GM; Oberg K; Vezzadini P; Foschini MP; Stridsberg M
Virchows Arch; 2006 Apr; 448(4):399-406. PubMed ID: 16408221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]